2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment

被引:120
作者
Zhou, Liya [1 ,9 ]
Lu, Hong [2 ]
Song, Zhiqiang [1 ]
Lyu, Bin [3 ]
Chen, Ye [4 ]
Wang, Jiyao [5 ]
Xia, Jun [6 ,7 ]
Zhao, Zhan [8 ]
机构
[1] Peking Univ Third Hosp, Dept Gastroenterol, Beijing 100191, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Gastroenterol, Shanghai 200127, Peoples R China
[3] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Hangzhou 310018, Zhejiang, Peoples R China
[4] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangzhou 510515, Guangdong, Peoples R China
[5] Fudan Univ, Affiliated Zhongshan Hosp, Dept Gastroenterol, Shanghai 200032, Peoples R China
[6] Univ Nottingham Ningbo China, Nottingham China Hlth Inst, Nottingham Ningbo GRADE Ctr, Ningbo 315100, Zhejiang, Peoples R China
[7] Univ Nottingham, Sch Med, Acad Unit Lifespan & Populat Hlth, Nottingham, England
[8] Systemat Review Solut Ltd, Shanghai 201403, Peoples R China
[9] Peking Univ Third Hosp, Dept Gastroenterol, 49 North Garden Rd, Beijing 100191, Peoples R China
关键词
Helicobacter pylori; Peptic ulcer; Guideline; Pharmacological treatment; CONTAINING QUADRUPLE THERAPY; TYPE-2; DIABETES-MELLITUS; STANDARD TRIPLE THERAPY; BISMUTH QUADRUPLE; ANTIBIOTIC-RESISTANCE; 2ND-LINE REGIMENS; 1ST-LINE THERAPY; NON-INFERIORITY; PLUS BISMUTH; OPEN-LABEL;
D O I
10.1097/CM9.0000000000002546
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Helicobacter pylori (H. pylori) infection is an infectious disease with a prevalence rate of up to 50% worldwide. It can cause indigestion, gastritis, peptic ulcer, and gastric cancer. H. pylori eradication treatment can effectively control disease progression and reduce the risk of the above conditions. However, the escalating trend of antibiotic resistance presents a global challenge for H. pylori eradication. We aim to provide guidance on pharmacological treatment of H. pylori infection.Methods: This clinical practice guideline is developed following the World Health Organization's recommended process, adopting Grading of Recommendations Assessment, Development and Evaluation in assessing evidence quality, and utilizing Evidence to Decision framework to formulate clinical recommendations, minimizing bias and increasing transparency of the clinical practice guideline development process. We used the Reporting Items for practice Guidelines in HealThcare (RIGHT) statement and The Appraisal of Guidelines for Research and Evaluation II (AGREE II) as reporting and conduct guides to ensure the guideline's completeness and transparency.Results: Though decreasing in developed countries, the prevalence of H. pylori remains high in developing countries, causing a major public health burden. This clinical practice guideline contains 12 recommendations concerning pharmacological treatment for H. pylori eradication. Among them, it is worth highlighting that bismuth preparations are inexpensive, safe, and effective, consequently making bismuth quadruple therapy a preferred choice for initial and rescue treatment. In empirical treatment, high dose dual therapy is equally effective compared with bismuth quadruple therapy.Conclusions: The 12 recommendations in this clinical practice guideline are formed with consideration for stakeholders' values and preferences, resource use, feasibility, and acceptability. Recommendations are generalizable to resource limited settings with similar antibiotic resistance pattern as China, and lower middle-income countries facing comparable sociological and technical challenges.
引用
收藏
页码:2899 / 2910
页数:12
相关论文
共 106 条
[1]  
Abdulridha MK., 2018, ASIAN J PHARM CLIN R, V11, P460
[2]   Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen [J].
Aksoy, Evrim Kahramanoglu ;
Sapmaz, Ferdane Pirincci ;
Goktas, Zeynep ;
Uzman, Metin ;
Nazligul, Yasar .
MEDICAL PRINCIPLES AND PRACTICE, 2017, 26 (06) :523-529
[3]   Quadruple therapy versus standard triple therapy for eradication of Helicobacter pylori in Kuwait [J].
Alboraie, Mohamed ;
Saad, Motaz ;
Al-Ali, Jaber ;
Malik, Mohammad ;
Asem, Noha ;
Schmidt, Imre ;
Alfadhli, Ahmad A. .
ARAB JOURNAL OF GASTROENTEROLOGY, 2015, 16 (3-4) :131-135
[4]   GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction [J].
Alonso-Coello, Pablo ;
Schunemann, Holger J. ;
Moberg, Jenny ;
Brignardello-Petersen, Romina ;
Akl, Elie A. ;
Davoli, Marina ;
Treweek, Shaun ;
Mustafa, Reem A. ;
Rada, Gabriel ;
Rosenbaum, Sarah ;
Morelli, Angela ;
Guyatt, Gordon H. ;
Oxman, Andrew D. .
BMJ-BRITISH MEDICAL JOURNAL, 2016, 353
[5]  
Aminian Keyvan, 2010, Trop Gastroenterol, V31, P303
[6]  
[Anonymous], 2011, J CLIN GASTROENTEROL, V45, P383, DOI 10.1097/MCG.0b013e31820fb8f6
[7]  
[Anonymous], 2014, GLOBAL TUBERCULOSIS
[8]   AGREE II: advancing guideline development, reporting and evaluation in health care [J].
Brouwers, Melissa C. ;
Kho, Michelle E. ;
Browman, George P. ;
Burgers, Jako S. ;
Cluzeau, Francoise ;
Feder, Gene ;
Fervers, Beatrice ;
Graham, Ian D. ;
Grimshaw, Jeremy ;
Hanna, Steven E. ;
Littlejohns, Peter ;
Makarski, Julie ;
Zitzelsberger, Louise .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2010, 182 (18) :E839-E842
[9]   Epidemiology of Helicobacter pylori infection [J].
Burucoa, Christophe ;
Axon, Anthony .
HELICOBACTER, 2017, 22
[10]   Penicillin Allergy [J].
Castells, Mariana ;
Khan, David A. ;
Phillips, Elizabeth J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (24) :2338-2351